StockWatch
·

Nanta Tech Ltd Q2 FY27 Results

NANTAQ2 FY27 Results
Filing
MetricValue (₹ Cr)
Revenue42.55
Total Income42.57
Expenditure35.79
PBT6.77
Net Profit5.07
OPM—
NPM11.91%
EPS9.89
View full financials
NANTA TECH LIMITED · H1 FY27 · THE VERDICT

97% growth, 45% guidance: The H2 test Nanta must pass

Nanta delivered a blowout H1 with 97.7% revenue growth and 131% PAT growth. Yet the company guided for 45–50% full-year growth, flagging sharp H2 deceleration. The market has marked it down 51% from its all-time high despite the execution—a miss that matters.

06 Nov 2026 · 6 min read
H1 FY27 Revenue

₹42.5 Cr

+97.7% YoY

H1 FY27 PAT

₹5.1 Cr

+131.4% YoY

EBITDA Margin (H1)

23.3%

+900 bps YoY

FY27 Full-Year Guidance

45–50%

revenue growth

Nanta delivered textbook execution in H1 FY27. Revenue of ₹42.5 Cr grew 97.7% year-on-year, driven by 200 robot deployments and the company's shift toward higher-margin robotics and AI work. Net profit surged 131% to ₹5.1 Cr, with EBITDA margins expanding a stunning 900 basis points to 23.3%. All claims made on the call—growth, margins, unit deployments—have been corroborated by the filed result. By any measure, this is strong.

The story, though, sits in the gap. FY27 full-year guidance of 45–50% growth is a dramatic deceleration from the 97.7% run-rate already posted in H1 alone. This implies H2 must slow to single digits or low teens—a cliff, not a glide. Management frames this as realistic caution; the market is reading it as a warning. And there's a second red flag: the company has guided for EBITDA margins of 20–22% for the full year, which is materially below the 23.3% already delivered in H1, signaling expected mix pressure or cost inflation as the year progresses.

What management claimed vs. what holds up

Validation of H1 claims against filed result

H1 revenue INR 42.6 Cr with 97.7% YoY growth

Filed result / corroboration

Delivered Q2 FY27: ₹42.5 Cr (matches exactly)

Verdict

Supported

PAT INR 5.1 Cr, up 131.4% YoY; PAT margin 11.9%

Filed result / corroboration

Delivered: ₹5.1 Cr PAT, 11.9% margin. Math checks: 5.1÷42.5 = 12%. Growth: 5.1 vs 2.2 prior = +131.8%

Verdict

Supported

EBITDA INR 9.9 Cr, margin 23.3%, up 900 bps YoY

Filed result / corroboration

9.9÷42.5 = 23.3%. Prior H1 FY26: ₹3.1 Cr (7.3% margin). 900 bps confirmed

Verdict

Supported

45–50% full-year FY27 growth is achievable and reflects market reality

Filed result / corroboration

H1 achieved 97.7%. FY27 guidance of 45–50% implies <0% to +20% H2 growth. Sustainable? Unproven

Verdict

Overstated—guidance implies severe H2 slowdown, not validated

EBITDA margin 20–22% for full year FY27

Filed result / corroboration

H1 already delivered 23.3%. Guidance implies margin contraction YoY

Verdict

Contradicted—guidance sits below H1 run-rate, signaling mix dilution or cost pressure

What changed on this call

  • RaaS model gaining momentum: now ~50% of H1 unit deployments; expected to increase in H2

  • Manufacturing model shifted to asset-light: signed MOU with Amitron (INR 10 Cr over 15 months); in-house assembly line by year-end

  • Segment focus narrowed: hospitality, warehouse automation, and defense are now explicit pillars; pulling back from consumer verticals

  • Order book visibility new: INR 60 Cr at end H1; anchors include Complex Cinema (₹4.4 Cr, 36 months), Pointer Insurance (₹6 Cr indicative), Amitron deal, and defense Phase-1

  • No FY28 target set: MD declined to confirm prior INR 200 Cr (March 2026 call) or any FY28 revenue goal; said 'focused on FY27 first'

How the street is positioned

Price action and valuation context. Nanta trades at ₹315 as of 2026-11-05, down 51.6% from its all-time high of ₹651.4. The stock sits above its 20-day SMA (₹312.89) but trades well below both the 50-day (₹333.14) and 200-day (₹366.33) moving averages, signaling a downtrend. RSI of 48.4 is neutral, neither oversold nor overbought. The 52-week range of ₹234–₹651.4 shows the stock has recovered 34.6% from its lows, but remains in the lower third of its yearly band. The drawdown from ATH is severe, and the price action does not reflect the strong H1 execution just reported.

Institutional flows. FII ownership has collapsed: from 2.15% in Q3 FY26 → 0.89% in Q4 FY26 → 0.00% in Q1 FY27 (a 215 basis point exodus in two quarters). DII has also trimmed, from 10.47% → 4.27% → 0.72% (down 975 basis points in the same span). Promoter ownership remains stable at 57.36%. The institutional pullback accelerated even as fundamentals improved—a tell that the market is pricing in execution risk or valuation concerns that the H1 print has not yet resolved.

What the tape is saying. The market's markup from ₹234 (low) to ₹651 (ATH) was a bet on early-stage robotics execution. The subsequent 51% drawdown reflects either (a) fear that H2 slowdown is real and guidance itself is at risk, (b) concern that RaaS model and asset-light manufacturing create unpredictable timing and margin pressure, or (c) simple valuation reset—a micro-cap roboticist in a nascent market may not command premium multiples even at 97% growth. The all-institutional outflows and the price stuck below its 50-day and 200-day averages suggest the market is still in wait-and-see mode despite strong results.

The bull-bear ledger

Two sides of the case
  • Execution on H1 targets was flawless: 97.7% growth, 131% PAT growth, 200 robot deployments all corroborated

  • Margin expansion is structural, not one-time: driven by higher-margin robotics mix (30–35% capex EBITDA vs 12–20% RaaS)

  • Order book visibility (₹60 Cr) provides 1–2 quarters of revenue runway

  • Large TAM in hospitality, warehouse, manufacturing, and defense; global robotics market USD 107 Bn by 2030

  • FY27 guidance (45–50%) is *much* lower than H1's 97.7% run-rate; implies sharp H2 slowdown or guidance miss risk

  • Margin guidance (20–22%) sits below H1's 23.3%, signaling expected mix or cost pressure in H2

  • No in-house manufacturing yet; dependent on Amitron outsourcing through EOY 2026

  • RaaS model complexity: 24–48 month payoff cycles, ties up capex, creates revenue timing risk

  • Customer concentration: top 2–3 deals (Complex Cinema, Pointer Insurance, Amitron, defense) represent material % of ₹60 Cr order book

  • FII/DII have exited 215/975 basis points respectively in 2 quarters; market still pricing execution risk

Risks, ranked by how much they should concern a holder

Risk matrix

1

High
Risk

H2 slowdown materializes; FY27 guidance missed

Why it matters

H1 achieved 97.7% growth, but FY27 guidance of 45–50% implies <20% H2 growth. If H2 comes in below guidance, the stock will re-rate sharply lower. Visibility into H2 order execution is the critical near-term test.

2

High
Risk

Margin dilution if RaaS model scales too aggressively

Why it matters

RaaS margins (12–20% AMC) are half of capex margins (30–35%). FY27 guidance for 20–22% EBITDA (vs 23.3% H1) signals this is already expected. If RaaS mix accelerates beyond plan, margins could compress further.

3

Medium
Risk

Manufacturing capacity bottleneck or Amitron delay

Why it matters

In-house assembly line not live until EOY. Any delay in Amitron's delivery or supply chain hiccup directly throttles H2/FY28 output. Company lacks control over this critical input.

4

Medium
Risk

Customer concentration; top 2–3 deals are major revenue sources

Why it matters

Complex Cinema and Pointer Insurance deals are large relative to ₹60 Cr order book. Early termination, scope cut, or integration failure at these customers would materially impact revenue and cash flow timing.

5

Medium
Risk

No FY28 target; guidance trajectory unclear

Why it matters

MD explicitly declined to confirm prior INR 200 Cr FY28 target or set new guidance. Market will be in limbo post-FY27 on whether Nanta is a 30% grower or a 100%+ grower. This uncertainty depresses valuation.

6

Low
Risk

Technology and IP obsolescence in fast-moving robotics sector

Why it matters

Nanta has 17 in-house robot models and proprietary software, but global players (ABB, KUKA, Boston Dynamics) have vastly larger R&D budgets. India-specific TAM focus helps, but tech risk remains for early-stage roboticist.

What to watch next

Three concrete milestones that resolve the debate
  • 1 · Q3 FY27 order inflow and deployment ramp

    The test is simple: do the 800+ robot deployments targeted for H2 materialize? Complex Cinema, Pointer Insurance, and defense Phase-1 are the big bets. If Q3 shows order delays, customer POC extensions, or deployment slippage, the H2 slowdown is real and FY27 guidance is at risk.

  • 2 · Margin trajectory in Q3; RaaS mix % disclosed

    FY27 guidance of 20–22% EBITDA is below H1's 23.3%. If Q3 margins continue to compress below 23%, it suggests RaaS is scaling faster than expected or costs are rising. If margins stabilize above 22%, mix is controlled.

  • 3 · FY28 guidance pre-announcement or call confirmation

    MD avoided FY28 targets on H1 call. By Q3/Q4, the market will demand clarity. If Nanta confirms 40–50% CAGR multi-year, moat strengthens. If FY28 guidance is vague or conservative, the market will assume management sees demand headwinds.

The single number to track

FY27 full-year revenue. If Nanta delivers on its 45–50% full-year growth guidance, the company will post ₹58–61 Cr revenue for FY27 (assuming FY26 base of ~₹40–43 Cr). This will validate management's H2 slowdown thesis and keep guidance credibility intact. If actual FY27 revenue undershoots 45% (i.e., comes in below ₹58 Cr), the stock will re-rate lower; if it overshoots 50% (i.e., ₹61 Cr+), the FY27 guidance was overly conservative and multi-year acceleration is credible. This one number will determine whether Nanta is a disciplined, de-risking growth story or a momentum miss waiting to happen.

Nanta Tech delivered impressive H1 execution. Revenue, profit, and unit deployments all came in as promised, and margins expanded sharply. The company is not a story of accounting creativity or one-time items—the growth is organic and the operational leverage is real. But the market is right to be cautious. The 97.7% H1 growth-to-45–50% full-year guidance reset is a red flag, not a baseline. Margin guidance sitting below H1 run-rate signals expected dilution. No FY28 target and a sharp institutional exit (FII gone, DII halved) tell you the market is pricing execution and visibility risk. Nanta must now prove H2 delivers on the 800+ robot deployment target and that margins hold. If it does, the 51% drawdown from ATH will look cheap in hindsight. If it doesn't, the stock has further to fall. This is a Hold—strong execution, but unproven sustainability and too much H2 risk to buy into the strength. Wait for Q3 to show H2 is real.

Informational and educational content only. Not investment advice.